View Archive »
About The Cover
The cover for issue 85 of Oncotarget features Figure 3, "Effect of cisplatin and MSC on brain functional connectivity," by Chiu, et al.
|
|
Table of Contents
Editorial
|
| Designing consensus immunogens to break tolerance to selfantigens for cancer therapy |
|
https://doi.org/10.18632/oncotarget.26275
|
| 35513-35514 |
|
| eIF4A inhibition: ready for primetime |
|
https://doi.org/10.18632/oncotarget.26268
|
| 35515-35516 |
Research Papers
|
| Decreased expression levels of complement regulator CD55 contribute to the development of bullous pemphigoid |
|
https://doi.org/10.18632/oncotarget.21216
|
| 35517-35527 |
|
| Distinct lung cancer subtypes associate to distinct drivers of tumor progression |
|
https://doi.org/10.18632/oncotarget.26217
|
| 35528-35540 |
|
| Lipid profiles of prostate cancer cells |
|
https://doi.org/10.18632/oncotarget.26222
|
| 35541-35552 |
|
| Retrospective analysis of prognostic factors in patients of papillary thyroid microcarcinoma |
|
https://doi.org/10.18632/oncotarget.26248
|
| 35553-35558 |
|
| MiR192 miR200c and miR17 are fibroblastmediated inhibitors of colorectal cancer invasion |
|
https://doi.org/10.18632/oncotarget.26263
|
| 35559-35580 |
|
| Nasal administration of mesenchymal stem cells restores cisplatininduced cognitive impairment and brain damage in mice |
|
https://doi.org/10.18632/oncotarget.26272
|
| 35581-35597 |
Corrections
|
| Correction: Resistin promotes tumor metastasis by downregulation of miR519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells |
|
https://doi.org/10.18632/oncotarget.26303
|
| 35598-35598 |
|
| Correction: Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells |
|
https://doi.org/10.18632/oncotarget.26304
|
| 35599-35599 |
|
| Correction: Sonoporation by microbubbles as gene therapy approach against liver cancer |
|
https://doi.org/10.18632/oncotarget.26305
|
| 35600-35600 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC